Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO) will participate in three investor conferences in November and December 2025. Scheduled events:

• TD Cowen Immunology & Inflammation Virtual Summit — Wednesday, November 12 at 1:30 PM PT / 4:30 PM ET.
• Jefferies Global Healthcare Conference, London — Tuesday, November 18 at 2:00 AM PT / 5:00 AM ET / 10:00 AM GMT.
• Piper Sandler 37th Annual Healthcare Conference — Tuesday, December 2 at 9:00 AM PT / 12:00 PM ET.

Any available webcasts will be posted under the Investors > News and Events section at the company website, with replays available for approximately 30 days after the live webcast.

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.

TD Cowen’s Immunology & Inflammation Virtual Summit
Wednesday, November 12
1:30PM PT/4:30PM ET

Jefferies Global Healthcare Conference in London
Tuesday, November 18
2:00AM PT/5:00AM ET/10:00AM GMT

Piper Sandler 37^th Annual Healthcare Conference
Tuesday, December 2
9:00AM PT/12:00PM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T^™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When will Allogene Therapeutics (ALLO) present at the TD Cowen Immunology & Inflammation Virtual Summit?

Allogene will present on Wednesday, November 12, 2025 at 1:30 PM PT / 4:30 PM ET.

What time is Allogene scheduled to speak at the Jefferies Global Healthcare Conference in London (ALLO)?

Allogene is scheduled for Tuesday, November 18, 2025 at 2:00 AM PT / 5:00 AM ET / 10:00 AM GMT.

When is Allogene's presentation at the Piper Sandler 37th Annual Healthcare Conference (ALLO)?

Allogene will present on Tuesday, December 2, 2025 at 9:00 AM PT / 12:00 PM ET.

Where can investors watch Allogene (ALLO) webcasts and replays from the November–December 2025 conferences?

Webcasts and replays will be posted to www.allogene.com under Investors > News and Events; replays will be available for about 30 days.

Will Allogene (ALLO) provide a replay if I miss a live investor presentation?

Yes. A replay will be posted on the company website and available for approximately 30 days after the live webcast.